

What is claimed is:

- 5
1. A method of treating a subject, comprising:  
introducing into said subject a peritoneal dialysis fluid which includes an inhibitor of  
a PKC, thereby treating said subject.
2. The method of claim 1, wherein said inhibitor is a specific inhibitor of  
PKC.
- 10
3. The method of claim 2, wherein said inhibitor is selected from the group  
consisting of: an inhibitor of a PKC  $\beta$ , an inhibitor of PKC  $\gamma$ , and an inhibitor of PKC  
 $\delta$ .
- 15
4. The method of claim 2, wherein said inhibitor is an inhibitor of PKC  $\beta$ .
5. The method of claim 4, wherein said inhibitor is an inhibitor of PKC  $\beta$ 1.
6. The method of claim 4, wherein said inhibitor is a bis (indolyl) maleimide.
- 20
7. The method of claim 6, wherein said inhibitor is LY333531.
8. The method of claim 7, wherein said LY333531 is present in said dialysis  
fluid at about 1-1,000 nanometers.
- 25
9. The method of claim 1, wherein said dialysis fluid has a concentration of  
glucose of about 200nM.
10. The method of claim 1, wherein said subject has previously received  
peritoneal dialysis.

11. The method of claim 1, wherein said subject has been a peritoneal dialysis patient for at least 2 to 24 months.

5 12. The method of claim 1, wherein said subject has already developed permeability disjunction.

13. The method of claim 1, wherein said subject has not yet developed permeability disjunction.

10

14. The method of claim 1, wherein said subject is at risk for renal failure.

15. The method of claim 14, wherein said subject is in end-stage renal failure.

15 16. A peritoneal dialysis fluid comprising an inhibitor of a PKC.

17. The dialysis fluid of claim 16, wherein said inhibitor is a specific inhibitor of PKC.

20 18. The dialysis fluid of claim 17, wherein said inhibitor is an inhibitor of PKC  $\beta$ .

19. The dialysis fluid of claim 18, wherein said inhibitor is a bis (indolyl) maleimide.

25

20. The dialysis fluid of claim 19, wherein said inhibitor is LY333531.

21. The dialysis fluid of claim 20, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nanometers.

22. The dialysis fluid of claim 16, wherein said dialysis fluid has a concentration of glucose of about 200nM.

5  
Sub A1  
23. A method of making an improved peritoneal dialysis fluid, comprising:  
providing a peritoneal dialysis fluid; and  
adding to that fluid an inhibitor of a PKC, to thereby provide an improved dialysis fluid.

10  
Sub 31  
24. The method of claim 23, wherein said inhibitor is LY333531.

add  
32

0007ED 6544350